ADELAIDE, Australia, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Avance Clinical, a full-service biotech-focused global contract ...

The trial is assessing single and multiple ascending doses of MB‑388 in healthy volunteers.

BioCardia's CardiAMP cleared Japan's PMDA consultation - a first for catheter-delivered cardiac cell therapy.

Immunic (NASDAQ:IMUX) is preparing a Phase 3 trial of its experimental multiple sclerosis drug vidofludimus calcium in ...

Meaningful antitumor activity observed at the 3.0 mCi monotherapy dose with 75% disease control rate and durable disease stabilization; one of two confirmed responders remains on study ~40 weeks after ...

(9926.HK) today announced that results from a Phase II clinical study evaluating its first-in-class PD-1/VEGF bispecific ...

Zydus Therapeutics, a subsidiary of Zydus Lifesciences Limited, has announced encouraging results from its Phase 2b clinical ...

Soligenix, Inc.  (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...

In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, explains how FDA ...

Sionna Therapeutics is rated Hold after SION-719 failed its Phase 2a endpoint in cystic fibrosis when combined with Trikafta.